As a new-type foreign trade service provider driven by technological transformation and export business, HiSiaddi has built a "1+2+3+4=1" service system and can supply wild yam extract and diosgenin sourced from multiple well-known original manufacturers. Boasting over a decade of market experience and factory technical conversion partnerships, HiSiaddi possesses extensive expertise addressing product compliance issues. Below is a case study of HiSiaddi resolving compliance challenges for wild yam extract and diosgenin foreign trade.
Contact HiSiaddi customer service to consult further compliance questions regarding wild yam extract and diosgenin products.
Purchaser: PhytoVital GmbH, Munich, Germany, a mid-to-high-end pharmaceutical enterprise specializing in natural drug R&D for gynecological endocrine and menopausal applications. Its products are categorized as German OTC pharmaceuticals and premium dietary supplements, sold across German chain pharmacies, private medical institutions in multiple EU countries and high-end wellness centers in Switzerland. Raw material access enforces six mandatory entry specifications: EU EC396 226-item pesticide residue testing, German LFGB food raw material regulations, USP, EU REACH chemical registration, TGA equivalent compliance and FSMA import control. Pre-market launch prerequisites include EU drug regulatory raw material filing, ARTG declaration for importers, origin traceability and full documentation review for wild plant harvesting compliance. Non-standard diosgenin raw materials without legal wild harvesting certificates, full-item test reports or production filing records are strictly rejected.
Its core products are phytosterol soft capsules and composite tablets with diosgenin as the core pharmaceutical raw material, requiring wild Qinba Dioscorea zingiberensis extraction and 98.0% pharmaceutical-grade specifications. Annual planned procurement volume: 18.6 tons, scheduled for five separate shipments from Shanghai Port to Hamburg Port, Germany. The client previously sourced domestically refined saponin from Europe long-term, switching to Chinese sourcing in 2025 amid shrinking European raw material production capacity and rising costs. After independently contracting three Shaanxi plant extract factories for an initial 5.2-ton stock order, manufactured goods were loaded and shipped to Hamburg Port, Germany, before five critical compliance bottlenecks emerged: missing wild raw material harvesting qualification documents, incomplete REACH pre-registration materials, pesticide residue testing failing EC396 limits, production factories unfiled on the EU import white list for overseas manufacturers and certificate of origin formats incompatible with German customs declaration standards. Goods were detained in bonded warehouses by Germany’s Federal Office of Food and Agriculture, prohibiting warehousing, sorting and distribution. Combined daily port detention, warehousing and container demurrage fees reached 1,180 EUR. Failure to complete all compliance document rectification within 30 working days would result in full batch return or on-site destruction, halting the client’s new product launch plan and incurring losses exceeding 70,000 EUR from pre-development formula R&D and auxiliary material stockpiling.
The three original domestic suppliers could only provide basic COA test certificates and business licenses, lacking systematic understanding of the full EU import compliance framework and unable to complete supplementary filings for drug regulatory records, wild resource certificates, REACH registration and overseas factory filings. Multiple revisions of documentation by factory legal and foreign trade teams failed German customs pre-review. In an emergency, PhytoVital GmbH fully entrusted HiSiaddi Foreign Trade as a third-party compliance coordination service provider to comprehensively manage full-category compliance document rectification, supplementary declarations, retesting and factory qualification filing delivery, unblocking the full compliance chain spanning Chinese export customs declaration to EU import clearance.
After receiving the client’s entrustment, HiSiaddi compliance specialists retrieved the German customs official detention notice and regulatory rectification opinions, sorting five substantive compliance defects combining Sino-German bilateral trade regulations and EU raw material entry detailed rules:
Diosgenin raw materials are extracted from wild Qinba Dioscorea zingiberensis, a domestic wild medicinal economic plant. German drug regulators mandate imported raw materials to be accompanied by official wild medicinal herb fixed harvesting filing certificates issued by forestry authorities, cooperative harvesting ledgers and legal wild resource collection declarations to verify non-poached, non-endangered smuggled raw material sources. Original suppliers only provided simple sales contracts without official forestry and wildlife department harvesting approval documents, preventing EU regulatory authorities from completing origin traceability verification and triggering direct goods detention. Most domestic plant extract manufacturers only prioritize product content production without awareness of statutory wild plant raw material traceability requirements imposed by European and American regulators, failing to prepare forestry compliance documentation for standard shipments.
The diosgenin monomer compound is listed in the EU REACH Regulation Inventory of Existing Commercial Chemical Substances. Any raw material imported at volumes exceeding 1 ton/year requires advance completion of EU REACH pre-registration by export enterprises to obtain a unique registration number retrievable via the European Chemicals Agency (ECHA) system. None of the three manufacturing factories completed REACH pre-registration, lacking official registration documentation and resulting in German customs chemical regulatory authorities refusing import declaration acceptance.
Original factory testing only issued COA reports based on the 33-item pesticide residue standard of the Chinese Pharmacopoeia, omitting full testing for 226 pesticide residues, heavy metals, polycyclic aromatic hydrocarbons and mycotoxins mandated by EU EC396 regulations. Sampling retesting at German customs-designated third-party laboratories detected two trace organophosphorus pesticide residues slightly exceeding EU limits. Original test reports lacked signatures from ISO17025-accredited laboratories and thus carried no official recognition validity for EU regulators, suspending raw material release approval.
The EU enforces an overseas production enterprise access white list system for plant-derived pharmaceutical raw materials, requiring export factories to complete corporate information filing in the EU food and drug regulatory system to obtain an overseas manufacturer filing code. None of the three original factories completed EU corporate filing, leaving no matching factory compliance information in customs systems and preventing import declaration data entry.
Although original certificates of origin were issued by local commerce bureaus, errors existed in product Latin names, customs HS codes and raw material source labeling conflicting with German customs declaration specifications. Sanitary certificates lacked exit port customs quarantine signatures and batch-specific matching remarks, with misaligned document elements leading to repeated rejection post-revision without passing pre-review.
HiSiaddi rapidly assembled a special working group consisting of EU compliance legal specialists, plant extract quality control engineers, customs declaration specialists, EU certification consultants and domestic forestry compliance proxy specialists, collaborating simultaneously with local EU compliance agents, domestic origin regulatory authorities and CNAS-accredited testing laboratories. Work was divided into three modules: domestic document rectification, overseas sample retesting and EU online filing, completing all supplementary compliance documentation within 28 working days.
HiSiaddi dispatched staff to the Qinba origin region in Hanzhong, Shaanxi, coordinating local forestry and grassland bureaus and fixed wild medicinal herb harvesting cooperatives to complete supplementary filing of full official documentation for wild Dioscorea zingiberensis harvesting in compliance with China’s Wild Plant Protection Regulations and Measures for the Supervision and Administration of Import and Export Chinese Medicinal Materials. Supplementary documents included fixed harvesting approval filings for wild Dioscorea zingiberensis, annual harvesting quota certificates, field harvesting ledgers and legal raw material source declarations, all notarized in bilingual Chinese and English for entry into the German drug regulatory traceability system to complete legal filing of wild raw material sourcing and eliminate traceability non-compliance risks.
HiSiaddi partnered with local EU compliance firms to compile technical dossiers including diosgenin structural formulas, physical and chemical parameters, annual output and export tonnage, submitting expedited REACH pre-registration applications to the ECHA system. Official pre-registration certificates and exclusive registration codes were obtained within 12 working days, retrievable in real time via the ECHA official website to supply core chemical access compliance documentation.
Coordinate bonded warehouse regulatory authorities to permit small-batch sampling, entrusting domestic SGS (ISO17025-accredited laboratory) to conduct full-item retesting per EU EC396 standards for 226 pesticide residues. For batches with two slightly excessive pesticide residues, coordinate sorting and re-refining of remaining same-batch raw materials in factory inventory to eliminate non-compliant batches, issuing new full-item COA test reports with CNAS signatures formatted for EU recognition, submitting updated qualified reports to German regulatory authorities for filing.
Compile full factory compliance materials including GMP certificates, ISO22000, KOSHER and HALAL system certifications, factory production floor plans and full-process SOP production documents. HiSiaddi’s EU compliance agent submits overseas manufacturer filing applications via German drug regulatory systems to complete white list entry and obtain EU-recognized overseas factory filing codes, satisfying mandatory EU import enterprise access requirements.
Re-apply for updated certificates of origin, plant quarantine certificates and exit sanitary certificates via customs and CCPIT, strictly complying with German declaration specifications for accurate reporting of diosgenin Latin names, correct HS codes, raw material origins, production batches and factory filing numbers. All documentation maintains one-to-one matching with bills of lading, packing lists and commercial invoices, with bilingual Chinese-English content notarized to eliminate errors and omissions in document elements.
After full rectified documentation passed review by Hamburg Customs and German food regulatory authorities, the detained 5.2 tons of diosgenin raw materials successfully completed tax payment and customs clearance for release from bonded warehouses. Additional detention, warehousing and demurrage losses were reduced by 65% compared to initial projections. Raw materials entered the client’s German GMP formulation workshop for mass production, enabling two new menopausal OTC formulations to complete German drug regulatory ARTG filings and scheduled launch across German chain pharmacies, with terminal sales in the first quarter exceeding client projections by 31%.
Recognizing HiSiaddi’s one-stop resolution of full-chain compliance challenges, PhytoVital GmbH signed an annual procurement framework for 18.6 tons with HiSiaddi. The remaining 13.4 tons will be shipped in four subsequent batches, with HiSiaddi conducting pre-shipment compliance pre-review for every batch in advance including REACH document re-verification, pre-full EC396 testing, certificate of origin pre-review and updated factory filing information to eliminate compliance risks at the source. The following year, the client expanded distribution channels into Switzerland and Austria with additional procurement demand for low-impurity skincare-grade diosgenin, once again fully entrusting HiSiaddi to coordinate full domestic and foreign compliance workflows. Backed by this premium German pharmaceutical client partnership, HiSiaddi optimized standardized EU compliance document templates for diosgenin export, subsequently assisting three high-quality domestic plant extract factories to complete full EU compliance qualification upgrades and secure equivalent saponin orders from two premium pharmaceutical enterprises in the Netherlands and Belgium, consolidating a stable high-end EU raw material supply chain for domestically manufactured pharmaceutical-grade extracts.
This case clearly highlights massive compliance information gaps between domestic and international industries: most domestic plant extract manufacturers focus on extraction processes and active ingredient control yet lack systematic awareness of overseas national drug regulatory laws, chemical registration, cross-border wild medicinal herb access and customs declaration formatting standards. Routine shipments only include basic domestic qualifications and simplified test reports incompatible with strict import compliance standards imposed by mid-to-high-end European and American pharmaceutical enterprises. Meanwhile, mid-to-high-end European pharmaceutical enterprises such as Germany’s PhytoVital GmbH possess in-depth expertise in local drug regulatory laws and import access rules yet lack familiarity with China’s wild medicinal herb harvesting management policies, domestic export commodity inspection specifications and factory certification systems. Independent direct procurement easily triggers document shortages, goods detention at ports, full-batch return or destruction and substantial economic losses stemming from compliance traps.
Drawing on years of foreign trade compliance resources, global regulatory databases and partnerships with domestic and overseas certification institutions, HiSiaddi transcends the single-factory product sales perspective to implement front-end risk control across five critical compliance nodes: wild raw material resource compliance, overseas production enterprise filing, cross-border chemical registration, international standard full-item testing and standardized customs declaration documentation. Acting as a third-party compliance service provider bridging Chinese and foreign regulatory barriers, HiSiaddi helps mid-to-high-end overseas clients avoid import compliance risks and recover detention economic losses while forcing partner domestic factories to upgrade export compliance systems and escape low-price non-standard homogenization competition. Continuous deep cultivation of European and American high-end dietary and pharmaceutical raw material tracks via fully compliant pharmaceutical-grade products delivers long-term win-win outcomes for both supply and demand sides.
Contact HiSiaddi customer service to consult further compliance questions regarding wild yam extract and diosgenin products.
+86-13120989737 
info@hisiaddi.com 
English
